Spruce Biosciences, Inc. SPRB
43.31 USD +0.42 (+0.98%)
At closeNov 13, 2026, 4:00 PM EST
43.31 0.00 0.00%
After hours · Nov 13, 4:00 PM ET
41.41 Day range 43.38
38.98 52-week range 115.00
- YTD
- -50.28%
- 1 year
- -61.53%
News
benzinga.com Spruce Biosciences Q3 EPS $(8.51) Up From $(14.58) YoY Spruce Biosciences (NASDAQ:SPRB) reported quarterly losses of $(8.51) per share. This is a 41.63 percent increase over losses of $(14.58) per share from the same period last year.
businesswire.com Spruce Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…
benzinga.com Spruce Biosciences Separates CRHX-101 Program Into Adrenyx Biosciences, Plans Spin-Off To Stockholders Transaction Expected to Create Two Independent, Publicly Traded Companies with Distinct Strategic Priorities, Separate Capital Structures and Dedicated TeamsUp to $50 Million Committed to Adrenyx…
businesswire.com Spruce Biosciences Announces Separation of CRHX-101 (Formerly SPR-202) Program into Adrenyx Biosciences SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…
benzinga.com Citizens Reiterates Market Outperform on Spruce Biosciences, Maintains $144 Price Target Citizens analyst Jonathan Wolleben reiterates Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and maintains $144 price target.- benzinga.com Lake Street Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $149 Lake Street analyst Daniel Brims initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $149.
benzinga.com Spruce Biosciences Launches MPS3BStudy.com, Online Resource For Families And Caregivers Of Children With Sanfilippo Syndrome Type B Website Enables Families and Caregivers of Children with MPS IIIB to Learn About and Register Interest in the TA-ERT Expanded Access Program (EAP) and TrAnsform Confirmatory StudyTA-ERT EAP and…- benzinga.com Guggenheim Maintains Buy on Spruce Biosciences, Lowers Price Target to $104 Guggenheim analyst Debjit Chattopadhyay maintains Spruce Biosciences (NASDAQ:SPRB) with a Buy and lowers the price target from $123 to $104.
benzinga.com Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $144 Citizens analyst Jonathan Wolleben maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and lowers the price target from $150 to $144.- benzinga.com SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. Q2 EPS $(6.68) Misses $(5.80) Estimate SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. (OTC:SPRB) reported quarterly losses of $(6.68) per share which missed the analyst consensus estimate of $(5.80) by 15.17 percent. This is a 90.86…
- benzinga.com B. Riley Securities Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $160 B. Riley Securities analyst Madison El-Saadi initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $160.
- benzinga.com Spruce Biosciences Joins Russell 3000 Index, Effective June 29 Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical…
benzinga.com Guggenheim Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $123 Guggenheim analyst Debjit Chattopadhyay initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $123.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Stock Market Today: Dow Jones, S&P 500 Futures Edge Higher With Eyes On Iran Talks—Apple, UnitedHealth, 3M In Focus (UPDATED) (Editor’s note: The futures and ETFs data were updated.) U.S. stock futures rose on Tuesday following Monday's decline. Futures of major benchmark indices edged up, with negotiating teams from the…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Amazon Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket Amazon Inc (NASDAQ: AMZN) rose in pre-market trading after announcing a strategic collaboration with Anthropic to spend $100B on AWS.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket 
benzinga.com Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge 
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com US Stocks Mixed; Dow Falls 100 Points - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Why Concorde International Group Shares Are Trading Higher By 55%; Here Are 20 Stocks Moving Premarket 
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com Why Amplify Energy Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For November 16, 2022 Upgrades
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 413 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's session, 101 companies made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's trading, 517 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 838 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 1043 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday, 849 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 671 companies achieved new lows for the year.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's trading, 505 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's session, 291 companies made new 52-week lows. Also check out this: Insiders Buying These 4 Penny Stocks
- benzinga.com 63 Biggest Movers From Yesterday Gainers Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) shares surged 93.2% to close at $1.70 on Thursday. Kiora Pharmaceuticals recently appointed David Hollander, MD, MBA, to its Board of Directors.
- benzinga.com Stocks That Hit 52-Week Lows On Monday Before 10 a.m. ET Monday, 63 stocks made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday Before 10 a.m. ET on Friday, 29 companies hit new 52-week lows.
- benzinga.com 78 Biggest Movers From Yesterday Gainers Obalon Therapeutics, Inc. (NASDAQ: OBLN) shares climbed 115% to close at $2.30 on Monday after declining around 5% on Friday.